Dopamine Receptor Agonists

Back to all technologies
Download as PDF
65304
Dopamine is a neurotransmitter that is important in locomotor control, reward circuitry, cognitive function, prolactin release, and a variety of other key physiological functions. Dopaminergic dysfunctions have been implicated in many disorders including Parkinson's disease, schizophrenia, addiction, and ADHD. Dopamine receptor agonists are of interest in terms of finding successful therapies for these disorders. However, current D1 and D2 receptor agonists can have adverse side effects depending on the level and timing of use.

Researchers at Purdue University have developed a class of novel D1 dopamine agonists, or stimulants, which may be useful in treating the symptoms of Parkinson's disease and other working memory and cognitive deficits. This series of compounds has potent and selective activity at dopamine D1 receptors, making them useful therapeutic agents in hypodopaminergic conditions. Recent studies have also shown that dopamine D1 agonists are able to reverse drug-induced and age-related deficits in working memory.

Advantages:
-Novel class of dopamine agonists
-Potent and selective activity
-Clinical precedent

Potential Applications:
-Pharmaceutical industry
Oct 20, 2011
Utility Patent
United States
9,359,303
Jun 7, 2016

Apr 21, 2010
NATL-Patent
Japan
5734957
Apr 24, 2015

Apr 21, 2010
NATL-Patent
European Patent
2421862
Jun 11, 2014

Apr 21, 2010
NATL-Patent
United Kingdom
2421862
Jun 11, 2014

Apr 21, 2010
NATL-Patent
Switzerland
2421862
Jun 11, 2014

Apr 21, 2010
NATL-Patent
Ireland
2421862
Jun 11, 2014

Apr 21, 2010
NATL-Patent
Germany
2421862
Jun 11, 2014

Apr 21, 2010
NATL-Patent
Netherlands
2421862
Jun 11, 2014

Apr 21, 2010
PCT-Patent
WO
(None)
(None)

Apr 21, 2009
Provisional-Patent
United States
(None)
(None)
Purdue Office of Technology Commercialization
1801 Newman Road
West Lafayette, IN 47906

Phone: (765) 588-3475
Fax: (765) 463-3486
Email: otcip@prf.org